SCHEMBL22769734

SCHEMBL22769734

COc1cc2nccc(Oc3ccc(N(C(=O)C4(C(N)=O)CC4)c4ccc(F)cc4)cc3F)c2c2c1OCCO2

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RET P07949 5/20 0.56
MET P08581 8/20 0.55
KDR P35968 13/20 0.54
AXL P30530 4/20 0.47
MERTK Q12866 2/20 0.45
PDGFRB P09619 2/20 0.41
KIT P10721 2/20 0.41
FLT3 P36888 2/20 0.41
PLK4 O00444 1/20 0.41
STK25 O00506 1/20 0.41
CIT O14578 1/20 0.41
AURKA O14965 1/20 0.41
CHUK O15111 1/20 0.41
MUSK O15146 1/20 0.41
EPHB6 O15197 1/20 0.41
MAPK13 O15264 1/20 0.41
MAP3K13 O43283 1/20 0.41
DAPK3 O43293 1/20 0.41
MAP3K7 O43318 1/20 0.41
RIPK2 O43353 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22769702 0.92 MET (0.57) RETMETKDRAXLMERTK
SCHEMBL22769724 0.92 MET (0.55) RETMETKDRAXLMERTK
SCHEMBL22769718 0.92 MET (0.55) RETMETKDRAXLEGFR
SCHEMBL22769701 0.92 MET (0.56) RETMETKDRAXLMERTK
SCHEMBL22769711 0.91 RET (0.64) RETMETKDRAXLMERTK
SCHEMBL22769709 0.90 MET (0.69) RETMETKDRAXLMERTK
SCHEMBL22769706 0.90 MET (0.55) RETMETKDRAXLMERTK
SCHEMBL22769731 0.90 MET (0.55) RETMETKDRAXLMERTK
SCHEMBL22769710 0.90 MET (0.68) RETMETKDRAXLMERTK
SCHEMBL21246966 0.90 MET (0.55) RETMETKDRAXLMERTK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3750893-B1 DIOXAZOLINE COMPOUND, PREPARATION METHOD THEREFOR, AND USES THEREOF BEIJING SCITECH MQ PHARMACEUTICALS LTD (CN) 2023-04-19 EP disclosed
US-11407760-B2 Dioxinoquinoline compounds, preparation method and uses thereof BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) 2022-08-09 US disclosed
US-20200399285-A1 DIOXINOQUINOLINE COMPOUNDS, PREPARATION METHOD AND USES THEREOF ACCSALUS BIOSCIENCES LIMITED (VG) 2020-12-24 US disclosed
EP-3750893-A1 DIOXAZOLINE COMPOUND, PREPARATION METHOD THEREFOR, AND USES THEREOF Beijing Scitech-MQ Pharmaceuticals Limited (CN) 2020-12-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11407760-B2 Dioxinoquinoline compounds, preparation method and uses thereof KDR, MET, ABL1 RET 7/4885MET 2/4885KDR 1/4885
US-20200399285-A1 DIOXINOQUINOLINE COMPOUNDS, PREPARATION METHOD AND USES THEREOF KDR, MET, ABL1 RET 7/4885MET 2/4885KDR 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.